MX2019004030A - Inhibidores del receptor de glucocorticoides. - Google Patents

Inhibidores del receptor de glucocorticoides.

Info

Publication number
MX2019004030A
MX2019004030A MX2019004030A MX2019004030A MX2019004030A MX 2019004030 A MX2019004030 A MX 2019004030A MX 2019004030 A MX2019004030 A MX 2019004030A MX 2019004030 A MX2019004030 A MX 2019004030A MX 2019004030 A MX2019004030 A MX 2019004030A
Authority
MX
Mexico
Prior art keywords
compositions
inhibitors
compounds
glucocorticoid receptor
useful
Prior art date
Application number
MX2019004030A
Other languages
English (en)
Inventor
R Mcgee Lawrence
Eksterowicz John
C Medina Julio
Sun Daqing
Zhu Liusheng
Du Xiaohui
Yan Xuelei
Rew Yosup
R Fantin Valeria
Zhou Haiying
Delarae Balbas Minna
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of MX2019004030A publication Critical patent/MX2019004030A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a composiciones y métodos para tratar el cáncer y el hipercortisolismo. En este documento se proporcionan compuestos derivados de esteroides sustituidos y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones en cuestión son útiles para la inhibición de los receptores de glucocorticoides. Además, los presentes compuestos y composiciones son útiles para el tratamiento del cáncer.
MX2019004030A 2016-10-07 2017-10-06 Inhibidores del receptor de glucocorticoides. MX2019004030A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405801P 2016-10-07 2016-10-07
US201762526331P 2017-06-28 2017-06-28
PCT/US2017/055660 WO2018068021A1 (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor

Publications (1)

Publication Number Publication Date
MX2019004030A true MX2019004030A (es) 2019-09-16

Family

ID=61832215

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004030A MX2019004030A (es) 2016-10-07 2017-10-06 Inhibidores del receptor de glucocorticoides.
MX2021010252A MX2021010252A (es) 2016-10-07 2019-04-05 Inhibidores del receptor de glucocorticoides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010252A MX2021010252A (es) 2016-10-07 2019-04-05 Inhibidores del receptor de glucocorticoides.

Country Status (20)

Country Link
US (5) US10472387B2 (es)
EP (2) EP3851444A1 (es)
JP (2) JP6801093B2 (es)
KR (2) KR20210039001A (es)
CN (2) CN111690031B (es)
AU (3) AU2017339510B2 (es)
BR (1) BR112019006987B1 (es)
CA (1) CA3039636C (es)
DK (1) DK3523315T3 (es)
ES (1) ES2867853T3 (es)
HU (1) HUE054542T2 (es)
IL (2) IL265835B (es)
MX (2) MX2019004030A (es)
NZ (1) NZ753142A (es)
PL (1) PL3523315T3 (es)
PT (1) PT3523315T (es)
SG (1) SG11201903055UA (es)
SI (1) SI3523315T1 (es)
WO (1) WO2018068021A1 (es)
ZA (1) ZA202004440B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112902A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
NZ753142A (en) 2016-10-07 2020-08-28 Oric Pharmaceuticals Inc Inhibitors of glucocorticoid receptor
CN112272552A (zh) * 2018-04-11 2021-01-26 欧瑞克制药公司 包含糖皮质激素受体拮抗剂的固体形式和制剂及其用途
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists
US20230212215A1 (en) * 2020-05-08 2023-07-06 Trustees Of Dartmouth College Glucocorticoid receptor modulators
CN115915529A (zh) * 2021-09-30 2023-04-04 赛万特科技有限责任公司 发光控制方法、发光控制装置及发光装置
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JPH02188599A (ja) 1988-11-16 1990-07-24 Roussel Uclaf ３―ケト―デルタ―４，９―１９―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
DE4018167A1 (de) * 1990-06-01 1991-12-05 Schering Ag Verfahren zur herstellung von 10(beta)-h-steroiden
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
DE69413829T2 (de) 1993-08-04 1999-04-15 Akzo Nobel N.V., Arnheim/Arnhem Antiglucocorticoidsteroide zur behandlung von angststörungen
WO1995017192A1 (en) 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
PT806952E (pt) 1995-02-02 2003-08-29 Schering Ag Antagonistas da progesterona para a preparacao de medicamentos para o tratamento de hemorragias uterinas disfuncionais
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
CN1085078C (zh) * 1998-01-07 2002-05-22 沈志华 用于大月份引产的复合药物
US6512130B1 (en) 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
PT1989218E (pt) 2006-02-17 2010-02-01 Janssen Pharmactuica N V Derivados de 17-fósforo esteróides úteis como moduladores do receptor da progesterona
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
EP2148681B1 (en) 2007-04-20 2016-03-16 PregLem S.A. Selective progesterone modulators in the treatment of uterine bleeding
US8658128B2 (en) 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
EP2817019A4 (en) 2012-02-24 2016-04-06 Univ Chicago METHODS AND COMPOSITIONS ASSOCIATED WITH GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP3079475B1 (en) * 2013-12-11 2020-10-07 Sloan-kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
WO2017112902A1 (en) * 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CA3009525A1 (en) * 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
NZ753142A (en) 2016-10-07 2020-08-28 Oric Pharmaceuticals Inc Inhibitors of glucocorticoid receptor
US20200179404A1 (en) 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
CN112272552A (zh) 2018-04-11 2021-01-26 欧瑞克制药公司 包含糖皮质激素受体拮抗剂的固体形式和制剂及其用途

Also Published As

Publication number Publication date
AU2017339510A1 (en) 2019-05-23
CN111690031B (zh) 2021-06-01
KR20210039001A (ko) 2021-04-08
US20200291058A1 (en) 2020-09-17
SI3523315T1 (sl) 2021-08-31
HUE054542T2 (hu) 2021-09-28
US10472387B2 (en) 2019-11-12
PL3523315T3 (pl) 2021-10-18
US20200055892A1 (en) 2020-02-20
WO2018068021A1 (en) 2018-04-12
ES2867853T3 (es) 2021-10-21
SG11201903055UA (en) 2019-05-30
BR112019006987B1 (pt) 2021-05-04
AU2021202016B2 (en) 2022-01-06
NZ753142A (en) 2020-08-28
JP2019533651A (ja) 2019-11-21
US10836789B2 (en) 2020-11-17
IL265835A (en) 2019-06-30
MX2021010252A (es) 2021-09-21
AU2017339510B2 (en) 2020-07-30
AU2020213316A1 (en) 2020-08-27
AU2021202016C1 (en) 2022-06-09
US20190218246A1 (en) 2019-07-18
IL265835B (en) 2021-06-30
KR102237916B1 (ko) 2021-04-09
EP3851444A1 (en) 2021-07-21
CN110099915A (zh) 2019-08-06
DK3523315T3 (da) 2021-05-03
EP3523315B1 (en) 2021-03-24
US20210017219A1 (en) 2021-01-21
EP3523315A1 (en) 2019-08-14
US20230096870A1 (en) 2023-03-30
CA3039636C (en) 2023-04-11
BR112019006987A2 (pt) 2019-06-25
IL284005A (en) 2021-07-29
JP6801093B2 (ja) 2020-12-16
CN111690031A (zh) 2020-09-22
JP2021046409A (ja) 2021-03-25
ZA202004440B (en) 2022-07-27
US10723759B2 (en) 2020-07-28
AU2021202016A1 (en) 2021-04-29
AU2020213316B2 (en) 2021-03-11
KR20190083651A (ko) 2019-07-12
EP3523315A4 (en) 2020-04-15
CA3039636A1 (en) 2018-04-12
PT3523315T (pt) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2022005780A (es) Moduladores de receptores estrogenicos.
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2017016376A (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2017000450A (es) Compuestos terapeuticos inhibidores.
MX2020010900A (es) Inhibidores de demetilasa-1 especifica de lisina.
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EP4257591A3 (en) Inhibitors of lysine specific demethylase-1
WO2015184087A3 (en) Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
MX2017000170A (es) Inhibidores de demetilasa-1 especifica de lisina.
TW201613895A (en) Phosphatidylinositol 3-kinase inhibitors
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX369369B (es) Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
NZ743651A (en) Benzothiophene-based selective estrogen receptor downregulators
MX2018014114A (es) Derivados del sobetiroma.
EP3589289A4 (en) INHIBITION OF SMARCA2 FOR TREATMENT OF CANCER
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
MX2017003589A (es) Compuestos de indolinona y usos de los mismos.
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов